Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- LTT Bio-Pharma Starts PI Trial on PC-SOD
February 2, 2004
- Iryo Proverbs Reveal Japanese Spirit (17)
February 2, 2004
- Korosho Policies to Support Pharmaceutical Research Explained: Symposium
February 2, 2004
- Taisho Toyama Making Radical Changes in Marketing Strategy
February 2, 2004
- Six-year Interim Report of Japan Diabetes Complications Study Published
February 2, 2004
- Semi-annual Business Results
February 2, 2004
- Korosho to Approve Drug Sales by TV Phone on April 1
February 2, 2004
- Kuraya Sanseido Integrating Systems, Marketing Strategies Newly Start on Oct. 1
February 2, 2004
- BULLETIN
February 2, 2004
- FJPWA to Study Ways to Ensure Stable Profits for Wholesalers
February 2, 2004
- MEDICAL DEVICE NEWS IN BRIEF
February 2, 2004
- Biotech-related Market to Reach \1.1 Trillion in 2010: Fuji Keizai
February 2, 2004
- BULLETIN
February 2, 2004
- BUSINESS NEWS IN BRIEF
February 2, 2004
- DIAGNOSTIC NEWS IN BRIEF
February 2, 2004
- Off-label Use of 15 Drugs to Be Reimbursed
January 26, 2004
- Korosho Calls For Withholding of Applications in March
January 26, 2004
- REGULATORY NEWS IN BRIEF
January 26, 2004
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
January 26, 2004
- BULLETIN
January 26, 2004
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…